BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

GeoPharma, Inc. (GORX) Reports Patent Filing


10/19/2005 5:12:18 PM

LARGO, Fla., Nov. 29 /PRNewswire-FirstCall/ -- GeoPharma, Inc. today announced that Belcher Pharmaceuticals, Inc, wholly owned subsidiary of GeoPharma, Inc, has filed a patent on a novel method to stabilize the drug levothyroxine in a liquid form. Due to its novel form, one liquid dosage strength will replace up to 11 tablet strengths; which means distributors can eliminate from their shelves up to 11 strengths of the same drug. Additionally, the patent covers pediatric, geriatric, and veterinarian use. Levothyroxine Sodium is one of the most prescribed drugs in the United States with over 13 million patients. Levothyroxine Sodium, sold under the brand names Synthroid(R) (Abbott Laboratories), the second most prescribed drug in the United States and Levoxyl(R) (Mylan Laboratories), Soloxine(R) is used to treat hypothyroidisms and other thyroid disorders in humans and animals. The U.S. market for Levothyroxine Sodium Tablets is estimated to be approximately $1.3 billion in annual sales.

Belcher has commenced commercial production of stabilized levothyroxine sodium liquid and expects sales in the veterinarian channels by March 2005. "This is the second patent filed on the stabilization of Levothryroxine sodium as well as the third drug patent filed by Belcher. Successful completion of this project proves once again our technical capability and also our ability to look for new opportunities" says Dr. Kotha Sekharam, inventor and President of GeoPharma Inc.

ABOUT GEOPHARMA

GeoPharma, Inc. manufactures, packages, repackages and distributes a wide array of health-related products. GeoPharma, Inc. is comprised of the contract manufacturing entity, Innovative Health Products and its two wholly owned subsidiaries, Belcher Pharmaceuticals and Breakthrough Engineered Nutrition. Innovative Health Products custom manufactures high quality nutraceuticals, dietary and other nutritional supplements. Belcher Pharmaceuticals is an FDA registered plant that manufactures and distributes over-the-counter and generic drugs. Breakthrough Engineered Nutrition acts as the brand management and distribution arm of GeoPharma. Breakthrough distributes its own brands of convenience foods for consumers following low-sugar, low-carb and overall healthy lifestyles. Breakthrough's brands, CarbSlim and Lean Protein are distributed nationwide in both mass retail and specialty outlets. For more about GeoPharma, Inc. go to our websites at http://www.onlineihp.com/, http://www.leanprotein.com/ and http://www.carbslim.com/.

This press release contains certain forward-looking statements, including those regarding the company and its subsidiaries' expectations, intentions, strategies and beliefs pertaining to future performance. All statements contained herein are based upon information available to the company's management as of the date hereof, and actual results may vary based upon future events, both within and without management's control.

SAFE HARBOR PROVISIONS

Certain oral statements made by management from time to time and certain statements contained in press releases and periodic reports issued by GeoPharma, Inc. (the "Company"), as well as those contained herein, that are not historical facts are "forward-looking statements" within the meaning of Section 21E of the Securities and Exchange Act of 1934 and, because such statements involve risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements, including those in Management's Discussion and Analysis, are statements regarding the intent, belief or current expectations, estimates or projections of the Company, its Directors or its Officers about the Company and the industry in which it operates, and are based on assumptions made by management. Forward looking statements include without limitation statements regarding: (a) the Company's growth and business expansion, including future acquisitions; (b) the Company's financing plans; (c) trends affecting the Company's financial condition or results of operations; (d) the Company's ability to continue to control costs and to meet its liquidity and other financing needs; (e) the declaration and payment of dividends; and (f) the Company's ability to respond to changes in customer demand and regulations. Although the Company believes that its expectations are based on reasonable assumptions, it can give no assurance that the anticipated results will occur. When issued in this report, the words "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates," and similar expressions are generally intended to identify forward-looking statements.

Important factors that could cause the actual results to differ materially from those in the forward-looking statements include, among other items, (i) changes in the regulatory and general economic environment related to the health care and nutraceutical industry; (ii) conditions in the capital markets, including the interest rate environment and the availability of capital; (iii) changes in the competitive marketplace that could affect the Company's revenue and/or cost and expenses, such as increased competition, lack of qualified marketing, management or other personnel, and increased labor and inventory costs; (iv) changes in technology or customer requirements, which could render the Company's technologies noncompetitive or obsolete; (v) new product introductions, product sales mix and the geographic mix of sales and (vi) its customers' willingness to accept its Internet platform in the future. Further information relating to factors that could cause actual results to differ from those anticipated is included but not limited to information under the headings "Business," and "Management's Discussion and Analysis of Financial Conditions and Results of Operations" in this Form 10-KSB as of and for the year ended March 31, 2004 which was filed on June 29, 2004. The Company disclaims any intention or obligation to update or revise forward-looking statements, whether as a result of new information, future events or otherwise.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements which are not historical facts contained in this advertisement are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, governmental approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission

GeoPharma, Inc.

CONTACT: Dr. Kotha Sekharam for GeoPharma, Inc., +1-727-544-8866


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->